Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: PHB001
MIFTS: 41

Phobic Disorder

Categories: Mental diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Phobic Disorder

About this section

MalaCards integrated aliases for Phobic Disorder:

Name: Phobic Disorder 12 15 17
Phobic Anxiety Disorder 71
Phobic Disorders 43

Classifications:

MalaCards categories:
Anatomical: Mental diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:591
ICD9CM 34 300.20
MeSH 43 D010698
NCIt 49 C35420
SNOMED-CT 67 386810004
ICD10 32 F40
UMLS 71 C0349231
Sources

Summaries for Phobic Disorder

About this section
Disease Ontology : 12 An anxiety disorder where fear and anxiety are triggered by a specific stimulus or situation.

MalaCards based summary : Phobic Disorder, also known as phobic anxiety disorder, is related to agoraphobia and panic disorder. An important gene associated with Phobic Disorder is PRODH (Proline Dehydrogenase 1), and among its related pathways/superpathways are Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways and Serotonergic synapse. The drugs Topiramate and Paroxetine have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and eye, and related phenotypes are behavior/neurological and homeostasis/metabolism

Wikipedia : 74 A phobia is a type of anxiety disorder defined by a persistent and excessive fear of an object or... more...

Sources

Related Diseases for Phobic Disorder

About this section

Diseases related to Phobic Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 143)
# Related Disease Score Top Affiliating Genes
1 agoraphobia 30.8 WASF2 WASF1 SLC6A4 PIR NBAS MAOA
2 panic disorder 30.6 SLC6A4 MAOA HTR2A HTR1A CRH COMT
3 avoidant personality disorder 30.5 WASF2 WASF1 SLC6A4 PIR MAOA
4 depression 30.4 SLC6A4 MAOA HTR2A HTR1A CRH BDNF
5 phobia, specific 30.4 WASF2 WASF1 SLC6A4 PRODH OXT NBAS
6 generalized anxiety disorder 30.3 SLC6A4 PRODH MAOA HTR2A HTR1A COMT
7 social phobia 30.3 WASF2 WASF1 SLC6A4 SERPINA3 PRODH OXT
8 alcohol dependence 30.2 SLC6A4 OXT MAOA HTR2A HTR1A CRH
9 neurotic disorder 30.2 SLC6A4 MAOA HTR2A HTR1A BDNF
10 tic disorder 30.1 SLC6A4 PRODH MAOA HTR2A HTR1A COMT
11 acute stress disorder 30.1 SLC6A4 OXT CRH CFI BDNF
12 eating disorder 30.1 SLC6A4 HTR2A CRH COMT BDNF
13 obsessive-compulsive disorder 30.0 SLC6A4 OXT MAOA HTR2A HTR1A CRH
14 personality disorder 30.0 SLC6A4 MAOA HTR2A HTR1A CRH COMT
15 bulimia nervosa 30.0 SLC6A4 OXT MAOA HTR2A CRH COMT
16 anxiety 29.9 SLC6A4 PRODH OXT MAOA HTR2A HTR1A
17 alcohol use disorder 29.9 WASF2 WASF1 SLC6A4 HTR2A HTR1A CRH
18 anorexia nervosa 29.8 SLC6A4 OXT MAOA HTR2A HTR1A CRH
19 major depressive disorder 29.8 SLC6A4 OXT MAOA HTR2A HTR1A CRH
20 post-traumatic stress disorder 29.7 SLC6A4 MAOA HTR2A HTR1A CRH COMT
21 substance dependence 29.7 WASF2 WASF1 SLC6A4 SERPINA3 MAOA CRH
22 mental depression 29.3 WASF2 WASF1 SLC6A4 SERPINA3 PRODH OXT
23 psychotic disorder 29.3 SLC6A4 SERPINA3 PRODH OXT MAOA HTR2A
24 substance abuse 29.2 WASF2 WASF1 SLC6A4 SERPINA3 PRODH MAOA
25 schizophrenia 29.0 SLC6A4 SERPINA3 PRODH OXT MAOA HTR2A
26 dysthymic disorder 28.2 WASF2 WASF1 SLC6A4 SERPINA3 PRODH PIR
27 pyromania 10.5 WASF1 MAOA
28 barbiturate abuse 10.5 WASF2 WASF1 MAOA
29 dependent personality disorder 10.5 WASF2 WASF1 PIR
30 kleptomania 10.5 SLC6A4 MAOA HTR1A
31 histrionic personality disorder 10.5 WASF2 WASF1 PIR
32 inhibited male orgasm 10.5 SLC6A4 OXT HTR1A
33 paranoid personality disorder 10.5 WASF2 WASF1 PIR
34 hallucinogen dependence 10.4 WASF2 WASF1 COMT
35 voyeurism 10.4 PRODH MAOA ASPRV1
36 anterograde amnesia 10.4 PRODH HTR1A BDNF
37 animal phobia 10.4 OXT ASPRV1
38 cannabis dependence 10.4 WASF2 WASF1 COMT
39 ring dermoid of cornea 10.4 WASF2 WASF1 CGAS
40 retrograde amnesia 10.4 SLC6A4 HTR1A BDNF
41 tardive dyskinesia 10.4 HTR2A COMT
42 hypoactive sexual desire disorder 10.4 OXT HTR2A HTR1A
43 alcoholic psychosis 10.4 SLC6A4 HTR2A
44 pedophilia 10.4 OXT MAOA
45 drug psychosis 10.4 HTR2A HTR1A COMT
46 drug-induced mental disorder 10.4 HTR2A HTR1A COMT
47 aspiration pneumonitis 10.4 SERPINA3 OXT
48 bruxism 10.4 SLC6A4 HTR2A HTR1A
49 placenta disease 10.4 SERPINA3 PRODH OXT
50 exhibitionism 10.4 PIR MAOA CFI

Graphical network of the top 20 diseases related to Phobic Disorder:



Diseases related to Phobic Disorder
Sources

Symptoms & Phenotypes for Phobic Disorder

About this section

MGI Mouse Phenotypes related to Phobic Disorder:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10 BDNF CGAS COMT CRH FMR1 HTR1A
2 homeostasis/metabolism MP:0005376 9.77 BDNF CFI CGAS COMT CRH HTR1A
3 nervous system MP:0003631 9.4 BDNF COMT CRH FMR1 HTR1A MAOA
Sources

Drugs & Therapeutics for Phobic Disorder

About this section

Drugs for Phobic Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 63)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Topiramate Approved Phase 4 97240-79-4 5284627
2
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
3
Clonazepam Approved, Illicit Phase 4 1622-61-3 2802
4
Norepinephrine Approved Phase 4 51-41-2 439260
5
Sertraline Approved Phase 4 79617-96-2 68617
6
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
7
Tetracaine Approved, Vet_approved Phase 4 94-24-6 5411
8 Hypoglycemic Agents Phase 4
9 Cytochrome P-450 Enzyme Inhibitors Phase 4
10 Antipsychotic Agents Phase 4
11 Quetiapine Fumarate Phase 4 111974-72-2
12 Anticonvulsants Phase 4
13 Serotonin and Noradrenaline Reuptake Inhibitors Phase 4
14 GABA Modulators Phase 4
15 Venlafaxine Hydrochloride Phase 4
16 Neurotransmitter Agents Phase 4
17 Antidepressive Agents Phase 4
18 Serotonin Uptake Inhibitors Phase 4
19 Psychotropic Drugs Phase 4
20 Analgesics Phase 4
21 Poke Phase 4
22
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202
23
Cycloserine Approved Phase 3 68-41-7 401 6234
24
Citalopram Approved Phase 2, Phase 3 59729-33-8 2771
25
Yohimbine Approved, Investigational, Vet_approved Phase 2, Phase 3 146-48-5 8969
26
Propranolol Approved, Investigational Phase 2, Phase 3 525-66-6 4946
27
Fluoxetine Approved, Vet_approved Phase 3 54910-89-3 3386
28 Anti-Infective Agents Phase 3
29 Antitubercular Agents Phase 3
30 Anti-Bacterial Agents Phase 3
31 Antibiotics, Antitubercular Phase 3
32 Antimetabolites Phase 3
33 Yohimbe Phase 2, Phase 3
34
Guanfacine Approved, Investigational Phase 2 29110-47-2 3519
35
Peginterferon alfa-2a Approved, Investigational Phase 2 198153-51-4 5360545
36
Hydrocortisone Approved, Vet_approved Phase 2 50-23-7 5754
37
Hydrocortisone acetate Approved, Vet_approved Phase 2 50-03-3
38
St. John's Wort Approved, Investigational, Nutraceutical Phase 2 84082-80-4
39 Anti-Anxiety Agents Phase 2
40 Adrenergic alpha-Agonists Phase 2
41 Antihypertensive Agents Phase 2
42 Adrenergic Agents Phase 2
43 Adrenergic Agonists Phase 2
44 Antiviral Agents Phase 2
45 Narcotics Phase 2
46 Analgesics, Opioid Phase 2
47 Narcotic Antagonists Phase 2
48 Hydrocortisone 17-butyrate 21-propionate Phase 2
49 Anti-Inflammatory Agents Phase 2
50 Hydrocortisone hemisuccinate Phase 2

Interventional clinical trials:

(show top 50) (show all 105)
# Name Status NCT ID Phase Drugs
1 Topiramate Augmentation to a Selective Serotonin Re-uptake Inhibitor (SSRI) in Treatment-Resistant Generalized Social Phobia: A Double-Blind Placebo -Controlled Trial. Unknown status NCT00182455 Phase 4 Topiramate;Placebo
2 A Randomised, Triple Blind, Placebo-controlled Trial Comparing the Effects of Cognitive Therapy, Paroxetine and Both Cognitive Therapy and Paroxetine in the Treatment of Patients With Primary Social Phobia Completed NCT00184106 Phase 4 Seroxat, Cognitive therapy, Seroxat+ cognitive therapy
3 Improving Outcomes in Pharmacotherapy of Social Phobia Completed NCT00282828 Phase 4 Sertraline;Venlafaxine;Placebo;Clonazepam
4 The Use of Quetiapine (Seroquel) in the Treatment of Social Phobia: Effects on Cue Reactivity in Response to Virtual Reality Public Speaking Environment Completed NCT00407199 Phase 4 quetiapine
5 Sertraline in the Treatment of Generalized Social Phobia With Comorbidity Terminated NCT00182533 Phase 4 Sertraline;Placebo
6 A Randomized Controlled Study of the Effect of a Needle Phobia or Apprehension Intervention With or Without Synera® on Conversion From Central Venous Catheters to Arteriovenous Fistula or Graft Terminated NCT01623583 Phase 4
7 Transfer of Manualized Cognitive-Behavioral Therapy (CBT) for Social Phobia Into Clinical Practice (SophoPrax) Unknown status NCT01388231 Phase 2, Phase 3
8 Evaluation of the Effects of Post-Session Administration of D-cycloserine On Exposure Therapy Outcomes Completed NCT01102803 Phase 3 D-Cycloserine;Placebo
9 Placebo-Controlled Pilot Study of Escitalopram in the Treatment of Specific Phobia Completed NCT00121069 Phase 2, Phase 3 Escitalopram
10 Clinical Evaluation of BRL29060A (Paroxetine Hydrochloride Hydrate) in Social Phobia/Social Anxiety Disorder (SAD) -A Double-blind, Placebo-controlled Study- <Phase III Study> Completed NCT00318669 Phase 3 Paroxetine hydrochloride hydrate
11 Clinical Evaluation of BRL29060A (Paroxetine Hydrochloride Hydrate) in Social Phobia/Social Anxiety Disorder (SAD) -A Open-Label, Uncontrolled, Long-term Study- <Phase III Study> Completed NCT00264654 Phase 3 BRL29060A;paroxetine hydrochloride hydrate
12 Facilitation of Fear Extinction With Yohimbine Hydrochloride in Phobic Participants Completed NCT00734422 Phase 2, Phase 3
13 Noradrenergic Manipulation and Virtual Reality Exposure Therapy in Phobic Participants Completed NCT02007694 Phase 2, Phase 3
14 Treatment of Childhood Social Phobia Completed NCT00043537 Phase 3 Fluoxetine;Pill Placebo
15 A Randomized, Controlled Study of a Stepped-care Model for the Treatment of Social Phobia and Panic Disorder in Adults Completed NCT00619138 Phase 3
16 A Comparison Between Internet-based Self-help Therapy and Group Therapy for Social Phobia - A Clinical Equivalence Trial Using Cognitive Behavioural Therapy (CBT) Completed NCT00564967 Phase 3
17 Residential Cognitive Therapy Versus Residential Interpersonal Therapy for Social Phobia: A Randomized Controlled Trial Completed NCT00326430 Phase 2, Phase 3
18 Child/Adolescent Anxiety Multimodal Treatment Study Completed NCT00052078 Phase 3 Sertraline (SRT);Placebo
19 2/3 Treatment of Anxiety in Autism Spectrum Disorder Completed NCT02028247 Phase 3
20 The Efficacy of a VR Enhanced Video Exposure Therapy for Dental Phobia - a Randomized Controlled Trial Unknown status NCT03098134 Phase 2
21 Enhancing Exposure Therapy for Snake and Spider Phobias With Fear Retrieval and Compound Extinction Unknown status NCT02160470 Phase 1, Phase 2
22 One-Session Treatment for Specific Phobias in Children Completed NCT00051220 Phase 1, Phase 2
23 A Phase 2a Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multi-center Study Investigating the Efficacy, Safety, and Tolerability of JNJ-42165279 in Subjects With Social Anxiety Disorder. Completed NCT02432703 Phase 2 JNJ-42165279;Placebo
24 Anxiolytic Effects of Single-dose Quetiapine XR Administration on Clinical Symptoms and Amygdala Activation During Exposure in Patients With Simple Phobia Completed NCT00872716 Phase 2 Quetiapine XR
25 A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Tolerability of SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP). Completed NCT01470469 Phase 2 SPD503 (extended-release Guanfacine hydrochloride);Placebo
26 Double Blind Placebo Controlled Study of PH94B for Management of the Symptoms of Generalized Social Phobia Completed NCT01217788 Phase 2 PH94B intranasal spray
27 St. John's Wort Versus Placebo in Social Phobia Completed NCT00035412 Phase 2 St. John’s Wort
28 An fMRI Study Investigating the Effects of Acute D-cycloserine Administration on Brain Activations and Cognitive Functioning in Spider Phobia. Completed NCT00591825 Phase 2 D-cycloserine;Placebo
29 A Brief Behavioral Treatment for Anxiety in Young Children Completed NCT02051192 Phase 1, Phase 2
30 Effect of D-Cycloserine on Treatment of Social Phobia Completed NCT00128401 Phase 2 D-Cycloserine;Placebo
31 Pegasys VR: Integrating Virtual Humans in the Treatment of Child Social Anxiety Completed NCT02816684 Phase 2
32 A Phase 2a Study to Evaluate the Kappa Opioid Receptor As a Target for the Treatment of Mood and Anxiety Spectrum Disorders by Evaluation of Whether CERC-501 Engages Key Neural Circuitry Related to the Hedonic Response Completed NCT02218736 Phase 2 CERC-501;placebo
33 Effects of Low-Level Laser Stimulation With and Without Fear Extinction Training in the Modification of Pathological Fear Recruiting NCT02926352 Phase 1, Phase 2
34 Glucocorticoid Treatment for Social Phobia Terminated NCT01574014 Phase 2 Hydrocortisone;Placebo
35 Time Intensive Cognitive Behavioural Therapy for a Specific Phobia of Vomiting Using a Single Case Experimental Design Completed NCT02920814 Phase 1
36 Virtual Reality and Concept of Control in the Treatment of Acrophobia by Exposure to Virtual Environments: Comparative Test Unknown status NCT02020824
37 Cognitive Behavioural Therapy for Social Phobia in People With Bipolar Disorder: A Pilot Study Unknown status NCT01736631
38 Internet-delivered Transdiagnostic Intervention for Anxiety and Depression in Romania- A Randomized Control Trial Unknown status NCT02739607
39 Qualitative Evaluation of Therapeutic Alliance in Adolescent Psychiatry: Crossing Perspectives of Adolescents, Parents and Physicians Unknown status NCT03288649
40 Improving the Control of Fear: Healthy Adults to Pathological Anxiety Unknown status NCT03498599
41 D-Cycloserine as Enhancer of One-Session Treatment for Phobia of Heights in Adults Unknown status NCT01037101 D-Cycloserine;Placebo
42 The Experimental Study of Threat-Avoidance in Anxiety Patients: Behavioral, Emotional, and Neural Correlates Unknown status NCT02336802
43 Evaluation of Nonsurgical Periodontal Treatment in Patients With Social Phobia: a Randomized Controlled Clinical Trial Unknown status NCT03241277
44 Clinical Evaluation of a Fiber-optic Sensor System for Monitoring Respiration Activity and Heart Work During MRI Examinations Unknown status NCT03384849
45 Outcomes of Cognitive Behavioral Therapy (CBT) Interventions Provided by Unlicensed Professionals in a General Hospital Setting Unknown status NCT01075672
46 Anti-phobic and Safety Behaviors in the Treatment of Acrophobia Unknown status NCT02085343
47 Enhancing Exposure Therapy for Spider Phobia With the Use of Threat-Relevant and Threat-Irrelevant Opposite Actions Unknown status NCT02905279
48 The Efficacy of Cortisol in Combination With Behavioral Therapy in the Treatment of Phobias Completed NCT00451750 Cortisol
49 Treatment of Social Phobia: Mediators And Moderators Completed NCT00000370
50 Reduction of Claustrophobia During Magnetic Resonance Imaging: Randomized, Controlled Trial Completed NCT00715806

Search NIH Clinical Center for Phobic Disorder

Inferred drug relations via UMLS 71 / NDF-RT 50 :


gabapentin
gabapentin enacarbil
Paroxetine
Paroxetine Hydrochloride

Cochrane evidence based reviews: phobic disorders

Sources

Genetic Tests for Phobic Disorder

About this section
Sources

Anatomical Context for Phobic Disorder

About this section

MalaCards organs/tissues related to Phobic Disorder:

40
Brain, Testes, Eye, Amygdala, Cortex, Heart, Prefrontal Cortex
Sources

Publications for Phobic Disorder

About this section

Articles related to Phobic Disorder:

(show top 50) (show all 409)
# Title Authors PMID Year
1
Life satisfaction in persons with mental disorders. 61
32556822 2020
2
Dose Timing of D-Cycloserine to Augment Exposure Therapy for Social Anxiety Disorder: A Randomized Clinical Trial. 61
32496566 2020
3
Cortical oxygenation during exposure therapy - in situ fNIRS measurements in arachnophobia. 61
32135488 2020
4
Disgust and fear: common emotions between eating and phobic disorders. 61
29766462 2020
5
'Excess anxiety' and 'less anxiety': both depend on vestibular function. 61
31743237 2020
6
Anxiety Symptom Severity and Long-term Risk for Suicidal Behavior in Depressive Disorders. 61
31131922 2019
7
Skin fairness is a better predictor for impaired physical and mental health than hair redness. 61
31792316 2019
8
[Epidemiology of anxiéty disorders]. 61
32237614 2019
9
[Prognosis of anxiety disorders]. 61
32237615 2019
10
Anxiety symptoms in obsessive-compulsive disorder and generalized anxiety disorder. 61
31760413 2019
11
The Spectrum of Vestibular Migraine: Clinical Features, Triggers, and Examination Findings. 61
30737783 2019
12
The genetic and environmental structure of fear and anxiety in juvenile twins. 61
30708402 2019
13
Cannabidiol enhancement of exposure therapy in treatment refractory patients with phobias: study protocol of a randomized controlled trial. 61
30760241 2019
14
Risk of psychiatric disorders in rosacea: A nationwide, population-based, cohort study in Taiwan. 61
30466187 2019
15
The Diagnosis and Treatment of Anxiety Disorders. 61
30282583 2018
16
Fine motor ability and psychiatric disorders in youth. 61
29209833 2018
17
Anxiety After Stroke: The Importance of Subtyping. 61
29437982 2018
18
[Cognitive processes in patients with different structure of anxiety disorders]. 61
29652298 2018
19
[Frequency of physical symptoms in anxiety-depressive disorders: cross-sectional study in a population of 202 psychiatric consultants]. 61
31037209 2018
20
Common and distinct brain networks underlying panic and social anxiety disorders. 61
28642079 2018
21
[Subjective evaluation of the effect of single test doses of phenazepam and placebo in patients with anxiety disorders: a relationship with objective pharmaco-electroencephalography characteristics]. 61
30335073 2018
22
Hypnotic approach during dental treatment: analysis of descriptive data of a case series. 61
29460520 2018
23
Do Symptoms of Irritable Bowel Syndrome Improve when Patients Receive Cognitive Behavioural Therapy for Co-morbid Anxiety Disorders in a Primary Care Psychological Therapy (IAPT) Service? 61
28478779 2017
24
Factors related to the association of social anxiety disorder and alcohol use among adolescents: a systematic review. 61
28579354 2017
25
Changes in intensity of neurotic symptoms associated with reduction of suicidal ideation in patients who underwent psychotherapy in the day hospital for the treatment of neurotic and behavioral disorders. 61
28866722 2017
26
Comparing Trauma Exposure, Mental Health Needs, and Service Utilization Across Clinical Samples of Refugee, Immigrant, and U.S.-Origin Children. 61
28585740 2017
27
Cultural aspects of anxiety disorders in India. 61
28867936 2017
28
Fear of Vaginal Penetration in the Absence of Pain as a Separate Category of Female Sexual Dysfunction: A Conceptual Overview. 61
28467769 2017
29
Mental Disorders in People Affected by Thalidomide. 61
28377012 2017
30
Psychophysiological reactivity of currently dental phobic-, remitted dental phobic- and never-dental phobic individuals during exposure to dental-related and other affect-inducing materials. 61
28012301 2017
31
[Psychopathology of anxiety-phobic disorders that led to hospitalization in a psychiatric hospital]. 61
29265082 2017
32
Prevention of Mental Health Disorders Using Internet- and Mobile-Based Interventions: A Narrative Review and Recommendations for Future Research. 61
28848454 2017
33
Choking Phobia : An Uncommon Phobic Disorder, Treated with Behavior Therapy : A Case Report and Review of the Literature. 61
28638212 2016
34
Gambling Problems Among Community Cocaine Users. 61
26983825 2016
35
[Hypnosis for anxiety and phobic disorders: A review of clinical studies]. 61
26944812 2016
36
Disgust- and anxiety-based emotional reasoning in non-clinical fear of vomiting. 61
26117360 2016
37
The epidemiology of common mental disorders from age 20 to 50: results from the prospective Zurich cohort Study. 61
25802979 2016
38
The High Prevalence of Anxiety Disorders After Stroke. 61
26601725 2016
39
[Anxiety and fear in children and adolescents]. 61
27042718 2016
40
[Anxiety disorders diagnostic algorithm in cancer patients]. 61
30462459 2016
41
Family Aggregation and Risk Factors in Phobic Disorders over Three-Generations in a Nation-Wide Study. 61
26785257 2016
42
Psychiatric Morbidity in Patients with Chikungunya Fever: First Report from India. 61
26557595 2015
43
A Critical Comprehensive Review of Religiosity and Anxiety Disorders in Adults. 61
25480317 2015
44
[Anxiety disorders in older adults]. 61
26103112 2015
45
Changes Needed in the Classification of Anxiety Disorders in Childhood: Options for ICD-11. 61
26259415 2015
46
[The strategic psychotherapy in the treatment of mental and behavioral disorders of the anxiety spectrum]. 61
25953942 2015
47
[Prévalence et facteurs associés du panique et des troubles phobiques dans les structures de première ligne]. 61
25867148 2014
48
The structure of genetic and environmental risk factors for fears and phobias. 61
24384457 2014
49
Clinical effectiveness of interventions for treatment-resistant anxiety in older people: a systematic review. 61
25110830 2014
50
[Tension-type headache and mental disorders in children]. 61
24637825 2014
Sources

Variations for Phobic Disorder

About this section

Copy number variations for Phobic Disorder from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 94765 15 70400000 76100000 Copy number LOXL1 phobic disorder
Sources

Expression for Phobic Disorder

About this section
Search GEO for disease gene expression data for Phobic Disorder.
Sources

Pathways for Phobic Disorder

About this section

Pathways related to Phobic Disorder according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways 1
11.76 SLC6A4 MAOA HTR2A HTR1A BDNF
2
Serotonergic synapse 36
11.68 SLC6A4 MAOA HTR2A HTR1A
3
Neurotransmitter Clearance In The Synaptic Cleft 65
Show member pathways
 10.83 SLC6A4 MAOA COMT
4
Selective Serotonin Reuptake Inhibitor Pathway, Pharmacodynamics 60
10.7 SLC6A4 MAOA HTR2A HTR1A
5
noradrenaline and adrenaline degradation 1
Show member pathways
 10.61 MAOA COMT
6
Dopamine metabolism 1
10.51 MAOA COMT
7
Methylphenidate Pathway, Pharmacodynamics 60
Show member pathways
 10.29 SLC6A4 MAOA HTR1A COMT
Sources

GO Terms for Phobic Disorder

About this section

Cellular components related to Phobic Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 dendrite GO:0030425 9.35 HTR2A HTR1A FMR1 COMT BDNF
2 synapse GO:0045202 9.17 WASF2 WASF1 SLC6A4 HTR2A HTR1A FMR1
3 SCAR complex GO:0031209 9.16 WASF2 WASF1

Biological processes related to Phobic Disorder according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 viral process GO:0016032 9.95 WASF2 HTR2A FMR1 CGAS CFI
2 female pregnancy GO:0007565 9.71 OXT CRH COMT
3 vasoconstriction GO:0042310 9.58 SLC6A4 HTR1A
4 positive regulation of cAMP-mediated signaling GO:0043950 9.57 CRH CGAS
5 behavior GO:0007610 9.56 HTR2A HTR1A
6 response to drug GO:0042493 9.55 SLC6A4 HTR2A CRH COMT BDNF
7 sleep GO:0030431 9.52 OXT HTR2A
8 catecholamine metabolic process GO:0006584 9.51 MAOA COMT
9 dendrite extension GO:0097484 9.49 WASF1 BDNF
10 positive regulation of Arp2/3 complex-mediated actin nucleation GO:2000601 9.48 WASF2 WASF1
11 neurotransmitter catabolic process GO:0042135 9.46 MAOA COMT
12 dopamine catabolic process GO:0042420 9.43 MAOA COMT
13 serotonin receptor signaling pathway GO:0007210 9.4 HTR2A HTR1A
14 lamellipodium morphogenesis GO:0072673 9.37 WASF2 WASF1
15 sperm ejaculation GO:0042713 9.32 SLC6A4 OXT
16 response to ether GO:0045472 9.26 OXT CRH
17 regulation of serotonin secretion GO:0014062 8.96 HTR1A CRH
18 memory GO:0007613 8.92 SLC6A4 OXT HTR2A BDNF

Molecular functions related to Phobic Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 Arp2/3 complex binding GO:0071933 8.96 WASF2 WASF1
2 serotonin binding GO:0051378 8.8 SLC6A4 HTR2A HTR1A
Sources

Sources for Phobic Disorder

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....